Jounce up 5% on JTX-8064 data

|About: Jounce Therapeutics, Inc. (JNCE)|By:, SA News Editor

Jounce Therapeutics (NASDAQ:JNCE) is up 5% premarket on light volume in reaction to preclinical data on JTX-8064 presented at AACR in Atlanta.

The results supported the potential effect of JTX-8064, a monoclonal antibody, of inducing an anti-tumor immune response by binding to (inhibiting) a protein called LILRB2 (leukocyte immunoglobulin like receptor B2). When LILRB2 binds to certain molecules it suppresses immune cells called macrophages.

Phase 1 development should commence late this year.

Subscribe for full text news in your inbox